Menu

FDA Approves Infilbray for GD3 Neurological Symptoms

Author: medicalhalo
Release time: 2026-11-20 04:05:06

  Gaucher disease is an autosomal-recessive lysosomal storage disorder caused by deficient glucocerebrosidase,leading to glycosphingolipid accumulation in liver,spleen,bone marrow,and lung.Type 1 spares the brain;type 3(GD3)also involves the central nervous system,producing progressive ataxia,gait instability,dysarthria,oculomotor abnormality,and cognitive decline.Intravenous enzyme replacement therapy(ERT)controls visceral and hematologic disease but cannot cross the blood-brain barrier,leaving CNS pathology untreated—the long-standing gap in GD3 care.

  Mechanism:Infilbray(venglustat),developed by Sanofi’s Genzyme,is an oral glucosylceramide synthase inhibitor(GCSi).Instead of replacing the missing enzyme,it reduces synthesis of the toxic substrate upstream,and because the molecule penetrates the blood-brain barrier it lowers pathological lipid burden in both peripheral tissues and brain.

  Indication and use:FDA approval in November 2026 covers adult and pediatric GD3 patients weighing at least 15 kg,for treatment of disease-related neurological manifestations,once daily by mouth.Some patients continue ERT in parallel for visceral control;the decision is made by a rare-disease specialist.

  Pivotal data:Approval rests on phase 3 LEAP2MONO(NCT05222906)—randomized,double-blind,double-dummy,active-controlled,multicenter;43 patients aged≥12 years already stabilized on ERT;randomized to oral venglustat once daily or IV ERT every 2 weeks for 52 weeks;co-primary endpoints mSARA(ataxia)and RBANS(cognition).At week 52 the combined neurological statistical test favored venglustat(p=0.0179),and three of four key secondary endpoints(spleen volume,liver volume,hemoglobin)also improved.

  Safety:Most common events were headache,nausea,diarrhea,and splenomegaly(~14%in each arm).Clinicians must monitor for psychiatric adverse reactions including depression,suicidal ideation and behavior​throughout therapy;evaluate mood and mental status regularly.Animal findings suggest a potential lens/opacity risk in younger patients—periodic ophthalmology review is advised.Use in pregnancy can harm the fetus;effective contraception is required for people of reproductive potential.Interruptions,dose modification,or continued ERT should be specialist-directed.

  Meaning and limits:Infilbray moves GD3 treatment from“visceral-only”to“CNS-addressable,”a mechanistic turning point.It does not reverse established permanent neurological damage;the value is slowing progression and preserving residual function—earlier assessment means greater benefit.

[ 免责声明 ]  本页面内容来自公开渠道(如FDA官网、Drugs官网、原研药厂官网等),仅供持有医疗专业资质的人员用于医学药学研究参考,不构成任何治疗建议或药品推荐。所涉药品可能未在中国大陆获批上市,不适用于中国境内销售和使用。如需治疗,请咨询正规医疗机构。本站不提供药品销售或代购服务。